Alcatel-Lucent, Citigroup, Clearwire, Pfizer High Stock Demand Movers March 1st

Alcatel-Lucent (NYSE:ALU): Morgan Stanley believes Juniper could be week following recent share strength and due to near-term weakness in carrier spending. Shares are Underweight rated.

Citigroup Inc. (NYSE:C): Cash bonuses on Wall Street last year are expected to have fallen 14% from 2010 to $19.7B from $22.8B, according to a report released by New York state Comptroller Thomas DiNapoli, reports the Wall Street Journal.

Clearwire Corporation (NASDAQ:CLWR): According to a person familiar with the matter, LightSquared is considering hiring former Nextel CEO Tim Donahue as CEO, Reuters reports.

Pfizer Inc. (NYSE:PFE): Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) announced that the U.S. FDA has extended the action date by three months for the New Drug Application, or NDA, for Eliquis, or apixaban, for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The new Prescription Drug User Fee Act, or PDUFA, goal date is June 28. Subsequent to the filing of the NDA, the companies submitted additional information about the Eliquis clinical program to the FDA, which constitutes a major amendment to the application and will require additional time for review. The companies will continue to work closely with the agency to support the continued review of the NDA for Eliquis. At this stage there are no plans for an FDA advisory committee meeting to review the NDA for Eliquis.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at